CryoPort, Inc. (NASDAQ:CYRX) Receives $16.38 Consensus Target Price from Analysts

Shares of CryoPort, Inc. (NASDAQ:CYRX) have been given an average recommendation of “Moderate Buy” by the nine ratings firms that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $16.3750.

Several equities analysts have commented on CYRX shares. Weiss Ratings upgraded shares of CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 6th. Guggenheim raised their target price on shares of CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Craig Hallum lifted their target price on shares of CryoPort from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, June 3rd. Jefferies Financial Group set a $13.50 price target on shares of CryoPort in a research note on Monday, June 8th. Finally, KeyCorp increased their price target on shares of CryoPort from $15.00 to $17.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th.

Insider Activity

In other news, CFO Robert Stefanovich sold 169,427 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $16.27, for a total transaction of $2,756,577.29. Following the transaction, the chief financial officer owned 109,850 shares in the company, valued at approximately $1,787,259.50. This trade represents a 60.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ramkumar Mandalam sold 23,214 shares of CryoPort stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $15.44, for a total value of $358,424.16. Following the sale, the director directly owned 67,894 shares of the company’s stock, valued at approximately $1,048,283.36. The trade was a 25.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 227,641 shares of company stock valued at $3,622,515. 9.50% of the stock is owned by insiders.

Institutional Trading of CryoPort

Several hedge funds and other institutional investors have recently bought and sold shares of the business. UBS Group AG raised its stake in CryoPort by 6.8% in the fourth quarter. UBS Group AG now owns 1,421,884 shares of the company’s stock valued at $13,650,000 after purchasing an additional 90,363 shares in the last quarter. Penbrook Management LLC grew its stake in CryoPort by 251.6% during the first quarter. Penbrook Management LLC now owns 185,775 shares of the company’s stock worth $1,538,000 after buying an additional 132,940 shares in the last quarter. Meros Investment Management LP grew its stake in CryoPort by 13.9% during the fourth quarter. Meros Investment Management LP now owns 626,427 shares of the company’s stock worth $6,014,000 after buying an additional 76,687 shares in the last quarter. Granahan Investment Management LLC increased its holdings in CryoPort by 475.0% in the 1st quarter. Granahan Investment Management LLC now owns 231,138 shares of the company’s stock valued at $1,914,000 after buying an additional 190,938 shares during the period. Finally, First Eagle Investment Management LLC acquired a new position in shares of CryoPort in the 4th quarter valued at approximately $2,996,000. Institutional investors and hedge funds own 92.90% of the company’s stock.

CryoPort Stock Up 0.1%

NASDAQ:CYRX opened at $15.17 on Friday. CryoPort has a 12-month low of $6.69 and a 12-month high of $16.89. The firm has a market capitalization of $764.57 million, a price-to-earnings ratio of 11.24 and a beta of 1.88. The stock’s 50 day moving average price is $15.37 and its two-hundred day moving average price is $11.68.

CryoPort (NASDAQ:CYRX) last issued its earnings results on Monday, May 4th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%.The business had revenue of $47.80 million for the quarter, compared to the consensus estimate of $44.86 million. Equities research analysts expect that CryoPort will post -0.85 EPS for the current year.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.